Atricure stock kpis
Want to see ATRC full AI Analyst Report?
Revenue by Segment
Atricure reported revenue by segment of $154.45M in Q3 2026, up 0.6% from Q2 2026 and up 15.0% year over year. This is the highest value since 2021.
Shows how sales split across the company’s product lines and services, revealing which devices or consumables drive growth and profit. For Atricure, this highlights dependence on surgical ablation systems versus consumable disposables (and any emerging product lines), signals where adoption or pricing pressure could affect margins, and points to which segments offer the most upside if clinical adoption or reimbursement improves.
Atricure is transitioning from a MIS-dependent company to one driven by pain management, appendage management and open ablation—MIS revenue has steadily eroded while pain and appendage have accelerated, fueled by cryoSPHERE MAX, new clips and EnCompass adoption. That shift explains the stronger cash generation and raised adjusted‑EBITDA outlook, but investors should watch near‑term risks: international reimbursement softness, a manufacturing transition, anticipated IPR&D charges and new competitive entrants in appendage could compress GAAP margins and accentuate expected Q3 seasonality.
ATRC Revenue by Segment
| Period | Open Ablation | Minimally Invasive Ablation | Pain Management | Appendage Management | Total |
|---|---|---|---|---|---|
| Q3 2026Sep 30, 2026 | $54.18M | $7.29M | $30.50M | $62.48M | $154.45M |
| Q2 2026Jun 30, 2026 | $52.13M | $8.05M | $29.44M | $63.99M | $153.60M |
| Q1 2026Mar 31, 2026 | $48.60M | $8.30M | $24.35M | $60.01M | $141.25M |
| Q4 2025Dec 31, 2025 | $49.32M | $9.85M | $24.44M | $56.89M | $140.50M |
| Q3 2025Sep 30, 2025 | $46.44M | $9.29M | $22.92M | $55.62M | $134.27M |
| Q2 2025Jun 30, 2025 | $46.82M | $10.21M | $23.20M | $55.91M | $136.14M |
| Q1 2025Mar 31, 2025 | $42.30M | $10.49M | $19.06M | $51.77M | $123.62M |
| Q4 2024Dec 31, 2024 | $42.00M | $13.02M | $19.64M | $49.62M | $124.28M |
| Q3 2024Sep 30, 2024 | $39.21M | $12.80M | $17.90M | $46.00M | $115.91M |
| Q2 2024Jun 30, 2024 | $39.93M | $13.59M | $16.25M | $46.50M | $116.27M |
| Q1 2024Mar 31, 2024 | $37.20M | $14.43M | $13.68M | $43.54M | $108.85M |
| Q4 2023Dec 31, 2023 | $35.77M | $14.53M | $13.75M | $42.50M | $106.54M |
| Q3 2023Sep 30, 2023 | $33.85M | $12.47M | $13.14M | $38.83M | $98.29M |
| Q2 2023Jun 30, 2023 | $34.72M | $12.74M | $13.03M | $40.42M | $100.92M |
| Q1 2023Mar 31, 2023 | $32.43M | $11.50M | $11.30M | $38.27M | $93.49M |
| Q4 2022Dec 31, 2022 | $30.93M | $11.44M | $11.42M | $34.23M | $88.03M |
| Q3 2022Sep 30, 2022 | $28.25M | $11.52M | $10.63M | $32.84M | $83.25M |
| Q2 2022Jun 30, 2022 | $28.28M | $11.43M | $10.32M | $34.50M | $84.53M |
| Q1 2022Mar 31, 2022 | $25.47M | $10.15M | $8.15M | $30.81M | $74.58M |
| Q4 2021Dec 31, 2021 | $24.11M | $13.01M | $6.97M | $29.13M | $73.22M |
| Q3 2021Sep 30, 2021 | $24.58M | $11.84M | $6.26M | $27.77M | $70.46M |
| Q2 2021Jun 30, 2021 | $25.03M | $11.28M | $5.72M | $29.35M | $71.38M |
| Q1 2021Mar 31, 2021 | $21.87M | $9.66M | $3.90M | $23.84M | $59.27M |

